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Abstract 
Pharmaceutical manufacturing industry is research-based, technology-intensive and highly 
controlled. Many African countries lack capacity to manufacture essential medicines and 
partnerships may be necessary for leverage of knowledge and technology which are the basis 
for innovation. This study aimed to establish the innovation capacity of the Eastern Africa 
pharmaceutical manufacturing industry, identify barriers to Public/Private Partnerships and 
establish a framework for an impactful pharmaceutical cross-sector partnership system which 
is pivotal in competitiveness of the industry. 
 
A survey was conducted in the pharmaceutical manufacturing industry, academia and 
research institutions. The data collection method encompassed comprehensive review, 
analysis of relevant literature, face-to-face interviews and filling in of structured 
questionnaires by respondents.  
 
There are about 60 pharmaceutical manufacturers in the region; 35 in Kenya, 11 in Uganda 
12 in Tanzania and 9 in Ethiopia. They produce mostly non-sterile medicines  comprising 
tablets, capsules, syrups, suspensions, ointments and creams. Only 28% of the products in the 
national essential medicines are currently being produced, majority being for management of 
communicable diseases. Average production capacity utilization was 43% for kenya. Research 
and Development scientists and personnel with special skills are few.  Respondents stated 
that policies impacting local industry were incoherent, insufficient and lacked consultation 
during formulation. Furthermore, there is  no linkage between academia,  research institutes 
and pharmaceutical industry. An industry-research institution partnership for product 
innovation  in line with public health priorities  articulated by the government is necessary.  
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Introduction 
Essential medicines are priority for the well-being of a nation and as such access to safe, effective and 
quality medicines for all is imperative as envisaged in the Sustainable Development Goal No. 3 of the 
United Nations.1 However, access to quality-assured essential medicines remains a challenge, with 
more than two billion people worldwide, majority being in developing countries lacking regular access 
to these products.  According to the World Health Organization (WHO) World medicines situation, 
two-thirds of the value of medicines produced globally is accounted for by firms with headquarters 
located in just five countries - the USA, Japan, Germany, France and the UK.2 The pharmaceutical 
industry in most countries in Africa has inadequate research and development (R&D) capacity. 
Majority of the manufacturers produce non-sophisticated products with limited specialized 
formulations to tackle the new emerging trends.  In view of this, the WHO, United Nations Conference 
on Trade and Development (UNCTAD), United Nations Industrial Development Organization (UNIDO) 
and other partners are advancing activities that enhance medicines access in developing countries. 
These include promoting investment in domestic industry to upgrade production and human capacity, 
developing coherent policy frameworks, utilization of Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS) flexibilities, and supporting national intellectual property (IP) 
legislation reforms. The goal of these initiatives is to enable developing countries to achieve national 
reliance in essential medicines through local production. 
 
The drug development is an expensive and laborious process that requires technological know-how, 
skilled researchers, political will and a regulatory framework that protects and rewards innovation. 
The R&D is also a high-risk undertaking, marked with high failure rates and the cost to identify 
innovative compounds may exceed USD 2 billion.3,4,5  To this end, collaborative/partnerships strategies 
such as mergers and acquisitions are increasingly seen as a means to expand business, capacity and to 
                                                             
1 Sustainable Development Goals; SDG 3: Division for Sustainable Development, Department of Economic and 
Social Affairs, United Nations, and New York. Retrieved from: https://sustainabledevelopment.un.org/sdg3. 
 
2 World Health Organization (WHO). (2004). The World Medicines 
situationhttps://apps.who.int/medicinedocs/en/d/Js6160e/3.html, [accessed 14 June 2019] 
3 M.S. Raghavendra, John R. Raj, A. Seetharaman (2012). A study of decrease in R&D spending in the 
pharmaceutical industry during post-recession. International Journal of Academic Research Part B; 2012; 4(5), 
29-47. 
4 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). (2014). The pharmaceutical 
industry and global health facts and figures 2014. 
5 International federation of pharmaceutical manufacturers & Associations (IFPMA). (2017).   Pharmaceutical 
Innovation and Public Health. Facts & Figures 2017. 
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improve profitability.6 Most of the leading pharmaceutical manufacturers are born out of one or more 
mergers, for example, GlaxoSmithKline’s originators include Glaxo, Wellcome, Smith Kline and 
Beecham. Partnerships leverage on collaborators’ complementary expertise, resources and share risks 
in order to improve capacities and expand market networks.7,8  Private pharmaceutical companies 
partner with publicly funded research organizations (e.g. universities or research institutes) to develop 
new products. Public-private partnerships (PPPs) is a strategy by which manufacturers exploit 
synergies in application and utilization of knowledge and resources, by establishing R&D priorities and 
optimize the use of available resources. Data analysis shows that the transformation of US leading 
pharmaceutical firms from basic production to research intensive institutions between the 1920s and 
1940s was accomplished through research collaboration with contract research organizations (CROs) 
and  university faculty.9,10    
 
  Notably some of these interventions are taking place in the East Africa Community (EAC) region. The 
interest in the local pharma business by international investors has seen acquisition of some 
companies, e.g. Universal Corporation Limited/Strides-Shasun merger (Kenya) and CIPLA/Quality 
Chemical Industries Limited (Uganda). This demonstrates that the pharmaceutical manufacturing 
industry is starting to embrace technological advancements that will significantly improve access to 
essential medicines.  Nonetheless, majority of pharmaceutical firms in EAC region continue to 
manufacture common products. A fraction of the listed essential medicines is produced mainly due to 
lack of infrastructure needed to develop new medicines. In a WHO background paper Report BP8.1,11 
PPPs were identified as a promising solution for addressing challenges in pharmaceutical innovation.  
 
                                                             
6 Yasin Çilhoroz, Cuma Sonğur , Mehmet Gözlü , and  Murat Konca. (2016). Mergers and acquisitions in 
pharmaceutical industry as a growth strategy: an investigation upon practice international journal of business 
and management vol. iv, no. 3 / 2016. doi: 10.20472/iac.2016.024.024  
7 Hilde Stevens  and Isabelle Huys (2017). Innovative Approaches to Increase Access to Medicines in Developing 
Countries. Front Med (Lausanne). 2017; 4: 218. Published online 2017 Dec 7. doi: 10.3389/fmed.2017.00218. 
8 Public-Private Partnerships for Improving Access to Pharmaceuticals (2002). Lessons from Field 
Implementation in Selected Countries, Initiative on Public-Private Partnerships for Health, Global Forum for 
Health Research. Published by The Initiative on Public-Private Partnerships for Health, Global Forum for Health 
Research, 2002. 
9 Jeffrey L. Furman and Megan MacGarvie (2009). Academic collaboration and organizational innovation: the 
development of research capabilities in the US pharmaceutical industry, 1927–1946* Article in Industrial and 
Corporate Change · September 2009  DOI: 10.1093/icc/dtp035.  
10 Michelle Palmera and Rathnam Chaguturub  (2017). Academia–pharma partnerships for novel drug discovery: 
essential or nice to have? Expert opinion on drug discovery, 2017 VOL. 12, NO. 6, 537–540 
https://doi.org/10.1080/17460441.2017.1318124. 
11 WHO background paper Report BP8.1: Public Private Partnerships. Elizabeth Ziemba, 2004. 
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The aim of this study was to establish the innovation capacity of the pharmaceutical manufacturing 
industry in the EAC region, identify the barriers to PPPs and establish a framework for an impactful 
pharmaceutical cross-sector partnership system. The specific objectives  of this research  were to, i) 
determine the level of production competence of the  pharmaceutical industry in EAC  region in 
regard to manufacture of national essential medicines, ii) identify policies and regulations that impact 
innovation and development of pharmaceutical products,  iii) establish mitigation strategies to reduce 
the product gap between the national essential medicines lists and medicines that are locally 
produced and iv) to explore how collaborations, financing, research links, and technology transfer can 
be harnessed to  boost production and access to  quality and affordable   medicines in the EAC region.  
The study was commissioned by Science Granting Councils Initiative (SGCI) in Sub-Saharan Africa and 
implemented by the African Centre for Technology Studies (ACTS) consortium. 
 
 Methodology  
A mixed methods research incorporating both elements of qualitative and quantitative approaches 
was used. Extensive literature review was performed followed by data collection using comprehensive 
structured questionnaires and formal semi-structured face to face (F2F) interviews. Three distinct 
questionnaires based on the objectives of this study were developed. The questionnaires were 
reviewed and pre-tested as per the work-plan to ensure that they were clear, concise and that they 
generate useful information. The respondents were pharmaceutical manufacturing industry, 
academia/research institutions and policy makers. Both close- and open-ended questions were 
adopted for the study. The questionnaire for the manufacturing industry comprised general questions 
on production competence, production capacity, good manufacturing practice certification, 
personnel, factors impacting local production, policies that impact product innovation and research 
collaborations with academia and research institutions. The other two questionnaires covered aspects 
of pharmaceutical public-private partnerships and policies. These later two were used to generate 
data from academia/research institutions and policy makers in the Ministry of Health, Trade & 
Industry. This study covered the EAC region and Ethiopia. 
 
Prior to data collection, the consultants met with Federation of Kenya Pharmaceutical manufacturers 
(FKPM), which is the umbrella body of pharmaceutical manufacturers in Kenya, to sensitize members 
on the data collection exercise and its importance. The questionnaire targeted to the industry was 
pretested with four Local Pharmaceutical Producers (LPPs) and the feedback used to refine the tool. 
The questionnaires were then administered to respondents by electronic mail and actively followed-
up with phone calls.  The questionnaire was distributed to all pharmaceutical manufacturers of 
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medicines for humans in Kenya and the rest of EAC region.  The questionnaire aiming at 
academia/research institutions was distributed to 4 academic institutions in Kenya (University of 
Nairobi, Kenyatta University, United States International (USIU) University and Mount Kenya 
University), Kenya Medical Research Institute (KEMRI)  and  2 schools of pharmacy in Tanzania 
(Muhimbili University of Health and Allied Sciences (MUHAS) and Kilimanjaro   of pharmacy). 
Interviews were conducted with the chairperson of FKPM, chief executive officers of five 
pharmaceutical manufactures in Kenya, government officials in the ministries of Health and Trade & 
Industry, the Kenya Investment Authority, Pharmacy and Poisons Board of Kenya) All data and 
feedback were collated and analyzed in line with the objectives of the study.  
 
Data Analysis 
The Kenya essential medicines list (EML) was analyzed by abstracting medicine entries using 
International Nonproprietary Names (INNs) and therapeutic classes in order to identify common 
medicines produced in Kenya and by extension the region considering that Kenya hosts the largest 
number of LPPs in the EAC region. A comparison of Kenya (EML with the registered products by LPPs 
was performed to identify the number of products listed on the EML produced in the region. The 
same dataset was also used to analysis the main therapeutic classes produced by manufactures in 
Kenya. Similarly, the human resource capacity and gaps in the pharma sector in different 
departments, including Research and Development (R&D) was evaluated by analyzing the number of 
personnel, qualification and experience in all departments at each of the manufacturing facilities. 
Production capacity utilization in the pharmaceutical industry was also determined. Comprehensive 
literature review and analysis of existing collaborations (academia, research institution, government 
and private sector) and case studies on successful and unsuccessful partnerships was performed.  All 
data and feedback from interviews were examined in line with the objectives of the study and the 






The level of production competence of the pharmaceutical industry in EAC region  
There are about 60 pharmaceutical manufacturers in EAC; 35 in Kenya, 11 in Uganda, and 12 in 
Tanzania. Ethiopia has 9 registered pharmaceutical manufacturers.  In Kenya, 16 firms (60% of the 25 
contacted) responded to the questionnaire. There was only one response from Tanzania (Zenufa 
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Laboratories) and one from Uganda (Abacus Pharma Limited). The low response from Uganda, 
Tanzania and Ethiopia is attributed to confidentiality and policy requirements on data sharing at both 
cooperate and government levels. As a counter measure, secondary data and public reference 
materials were used for these countries. The government of Kenya, academic and research 
institutions in Tanzania (3), and Kenya (5) also participated in the study. Likewise, feedback was 
received from Key Interview Informants (KIIs) from Kenya, Uganda, Tanzania and Ethiopia.  
 
Majority of manufacturers in the region produced non-sterile products – both beta and non-beta 
lactams. The major focus is on solids (capsules/tablets) and mostly the non-complicated formulations. 
One factory in Ethiopia and one in Uganda produce large-volume parenterals.  About 56% of the 
products manufactured were solid dosage forms, mostly tablets (Figure 1.0). Most of the solids are 
presented as strip/blister/bulk packs.  
 
 
Figure 1.0. Production capacities of LPPs in Kenya (n = 16) 
 
The pharmaceutical industry in Kenya produce about 130 products (~28%) out of 452 listed in the 
Kenya Essential Medicines List (EML). The same inference could be made about Ethiopia LLPs who 
produce only 90 of the listed 380 EML products. Notably, manufactures in Kenya continue to focus on 
a few therapeutic areas at the expense of the bigger need as per the disease burden profile of the EAC 
region and country.  From the essential medicines analysis, anti-infectives, non-opiods & Non-
steroidal anti-inflammatory medicines (NSAIMs) and respiratory conditions products are the most 
manufactured products in the region (Figure 2.0). Only 6% of the products manufactured were 
antivirals. There are attempts to manufacture products for the control of NCDs with a major focus on 
cardiovascular related products hence. There were 74 products registered by this industry for 
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period 2018/2019 were for non-communicable diseases and the balance for mostly communicable 
diseases. The product registration pipeline in Kenya had approximately 172 products from 16 
companies in various stages of dossier evaluation for product registration approval. About 40 
products were under development while another 84 were under consideration and a further 23 fully 
registered in 2019 at the time of the study. Access to new product registrations for Uganda, Tanzania 
and Ethiopia was not possible but a scan through the product lists of LPPs in these countries suggests 
that their focus is also on communicable diseases. 
 
Figure 2.0. EML produced in Kenya against the disease burden 
 
From the results, the production capacity utilization in the region was underutilized. The utilized 
capacity of Kenya pharmaceutical industry was 43% for non-beta lactam products (tablets, 48%, 
capsules, 28% and liquids, 52%). The respondents stated that there was no direct linkage between 
government and the industry that articulates prioritization of essential medicines requirements. 
 
 Skills Set for Pharmaceutical Sector 
The workforce at the 16 Kenyan firms that participated in this study was 3551. Nearly 20% held 
diploma or university level qualification and the rest were certificate graduates or had on- the- job 
training. The supervisory and managerial tasks for quality control (QC)/quality assurance (QA), and 
production departments are run by graduates with BSc, BPharm, MSc or PhD. Other skills available 
include craft certificates and O-level qualifications for various skills in plumbing, computer packages, 
electrical engineering, boiler operation, procurement and administration. The same picture likely 
occurs across the EAC region.  Data collated on Ethiopia and Uganda showed that the number of 
employees in the sector was approximately 2000 (2010) and 1800 (2014) for Ethiopia and Uganda 
respectively. Majority have qualification in chemistry, pharmacy, biochemistry etc. There was 
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formulation experts, process engineers, HVAC12 and IT specialists. In this study, LPPs placed more 
emphasis on the need of R&D, formulation, process optimization, validations and technology transfer 
skills. Most firms felt that they had adequate production, quality management skills.  
 
Policies and Regulations Impacting Innovation and Development of New Products in the Local 
Feedback received from CEOs of 5 leading companies indicate that there is   lack of clear government 
policy to support the local industry and  this has led to the manufacturers to be apprehensive when it 
comes to investing in their factories. The industry’s view was that there is no adequate incentives to 
catalyze investing in facility upgrading and quality improvement programs, especially in the 
production of donor funded products such as antiretrovirals and antimalarials. The executives felt that 
the return on investment (ROI)13 from such effort is negligible. Most LPPs indicated that policies and 
regulations are necessary for the growth of the industry and there are also policies which are directly 
related to the pharmaceutical manufacturing industry such as the price preference for procurement 
of local commodities and zero tariffs on most pharmaceutical inputs where manufacturers invest and 
claim tax rebates thereafter. However, this rebate process is bureaucratic and takes time to be 
effected disrupting the cash flow. Additionally, imported finished products are zero rated, and 
speedily available in the market once they are landed whereas manufacturing process takes time thus 
increasing the cost of locally produced medicines. This is further worsened by public tenders that are 
awarded based on the least bidder without regard to other considerations. In Kenya, distributors 
registered locally enjoy a 10% while a fully-fledged manufacturing firm has a 15% preference. Most of 
the CEOs interviewed felt strongly that the 5% differential between the two entities is insignificant 
considering the intensity of activities involved in pharmaceutical production. They were of the view 
that there is inadequate consultation with pharmaceutical manufacturing experts when formulating 
policies and that policies and regulations that impact local manufacturing industry are incoherent and 
inadequate. It is noteworthy that Ethiopia is more supportive to local production where these 
manufacturers are permitted a preference of up to 25% and awards 30% of the cost upfront and a 
surety of the remainder.  
 
The manufacture of pharmaceuticals in Kenya is regulated by Pharmacy and Poisons Board (PPB), 
which is the National Medicines Regulatory Authority (NMRA). All manufacturers were aware that all 
pharmaceutical products must be registered by the national medicines regulatory authorities 
                                                             
12 HVAC: Heating, ventilation, and air conditioning system are used to control the conditions within a 
manufacturing site.  This is a basic requirement for any pharmaceutical facility as part of GMP.  
13 ROI: Return on Investment.  
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(NMRAs) and compliance with GMP is mandatory for registration approval. Kenyan Pharmaceutical 
manufacturers have product registrations by NMRAs in several countries such as Uganda, Kenya, 
Tanzania, Malawi, Zambia and Mozambique. There are on-going activities on EAC harmonization of 
product registration and GMP inspections to ensure one standard quality of pharmaceutical products 
within the region. The EAC region has adopted the international and rigorous Common Technical 
Document (CTD) format of dossier submission which seemed to have slowed down of the registration 
process in Kenya. It was observed that in the period 2015/16 there was a 61% reduction in product 
registrations in Kenya with 20 new registrations in 2016 compared to and 51 in 2015. 
 
Pharmaceutical Sector Challenges; Gaps and Mitigation in Production of Essential Medicines 
 Most of the respondents were of the opinion that the industry  does not have the requisite know-
how and capability to manufacture  all formulations. This is true for all manufcaturers in the EAC 
region. There is inadequate investments in facility improvements and new technology in this industry. 
Attaining international GMP compliance remains a challenge in the region. In addition, the policies to 
support the local industry are inadequate, fragmented and incoherent.  Collaborations/Partnerships 
across LPPs, government and academic/research institutions are weak. In general, most companies 
believe that  government  policies, training, GMP compliance, manufcatruing and financing/markets 
are important factors to ensure succesfull production of essential medicines.  It was also observed 
that majority of the acturers manuprioritize market-demand products such as Over- The- Counter 
products than medicines on the EML. It was noted that most executives believe that skills is not a 
major factor for production of EML, with 50% of the respondents stating that there was no need to 
invest in skills.  
 
Compliance to Good Manufacturing Practices as a regulatory prerequisite for market authorization of 
pharmaceutical products  contributes immensely to the gap, especially with products that  require 
stringent operations such as parenteral preparations. Majority of respondents were of the opinion 
that  lack of strigent regulations to enforce GMP standards across the board allows for many entrants 
into the market without clear regulatory guideline for them to follow. Hence,  companies that have 
heavily invested to be GMP compliant as per regulatory requirements felt that there is no level-
playing field due to cost of compliance that makes them less competitive. For this reason, some 
companies tend to avoid investing heavily in product development because of the regulatory gap. This 
concern has  previously been raised with regulators by the stakeholders.14 Overall majority of the 
                                                             
14 Discussions with CEOs from the pharma companies 
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manufacturers view partnerships/collaborations and financing as major factors to consider in order to 
imporve pharma manufcaturing standards  and product range.  
 
Collaborations & Partnerships to Support Local Pharmaceutical Sector 
The finding of this study  was that  Kenya  manufactures only 28% of the medicines  on the  national 
essential medicine list. Kenya does not have adequate technical, financial and human capacity to 
produce all medicines on the essential medicines list. The LPPs were hesitant to engage in 
development of products that have high potential safety risks, narrow therapeutic indices and high 
product development costs. When asked about collaborations with other parties, 46% indicated that 
they had partnerships, but these  were operational collaborations. They also were congnizant of the 
fact that collaborations require  financial capital. 
 
 There are efforts by some manufacturers to utilize TRIPS flexibilities to manufacture ARVs. For 
instance, in 2004 Cosmos Limited, Kenya, negotiated with two companies, namely GlaxoSmithKline 
and Boehringer Ingelheim for voluntary license to produce ARVs in Kenya for the EAC region. This 
endeavor failed to supply on tender, partly due to the ever-changing ARV treatment regimen and the 
WHO Pre-qualification prerequisite for the manufacturing site since procurement of ARVs is donor 
funded. Other initiatives that are being harnessed to improve access to essential medicines include 
technology transfer and joint ventures. Examples of successful technology transfer enterprises in the 
EAC region are Universal Corporation Limited/Strides-Shasun merger (Kenya) and CIPLA/Quality 
Chemical Industries Limited (Uganda). Ethiopia has realized successful joint ventures which have 
contributed to growth of the pharmaceutical industry and also effectively transferred skill and 
technology. Pharmaceutical Joint venture in Ethiopia include Julphar Pharmaceuticals, Cadila 
Pharmaceuticals Ethiopia PLC, Sino-Ethiop Associate (Africa) PLC, Pharmacure PLC, East African 
Pharmaceuticals PLC (EAP) and Ethiopian Pharmaceutical Manufacturing (EPHARM).  There exists 
limited collaboration between the Pharmaceutical industry and Academia. In Tanzania, Muhimbili 
University, through the support of international partners have built a strong traditional medicines 
research portfolio with several potential molecules for management of conditions such as asthma, 
cholesterol and peptic ulcers. The university also has a research laboratory that is linked to the local 
pharmaceutical sector backed by memorandum of understanding. However, the uptake of their 
research services has been low.    
 
This study reveals that there is potential for growth in pharmaceutical research in the EAC region.  
There are efforts to promote R&D work at Muhimbili School of Pharmacy in Dar- es- Salaam, the 
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Kilimanjaro School of Pharmacy supported by German development agency and the Kenya Medical 
Research Institute (KEMRI) but this is at nascent stages. Furthermore, the region has many universities 
with schools offering courses in biological and other sciences and more than 10 schools of pharmacy 
which can partner with the pharmaceutical industry and explore collaborations for achieving national 
research agenda. From the information gathered in this project, it was  evident that the universities in 
the region  and research institutions have made little effort to  create  linkages with the 
pharmaceutical industry. Most  of the research that is perfomed  in these institutions is for academic 
publishing and has not resulted in innovation that is useful for the pharma industry. There is a clear 
disconnect between academia, research institutes, the  pharmaceutical industry and the government 
leading to a state of mistrust and misconception among these entities. Most companies indicated that 
their product development portfolio was based on market demand and not necessarily on the need to 
address government priorities. The academia  strongly felt  that the industry’s  main agenda  was 
tailored  towards  profit and  it  is necessary to re-engineer   management of the pharmaceutical 
industry  and  promote skills by  transforming   owneship from  family  to corporate govenannce. 
Absence of  information sharing platforms  for  the Industry, academia and research institutions was 
identified as  the key hinderance to collaborations and partnerships in EAC region. Most intervewees 
stated that the government should drive the pharmaceutical research agenda in the country. 
  
Disciusion 
The finding of this study is that only 28% of the listed essential medicines are produced locally. 
Various factors contribute to the inadequate capacity by the local industry in the EAC region to 
manufacture the required medicines. Tablets and liquid forms were majority most probably because 
the technology for production of these formulations are well established and readily accessible. It is 
also important to mention that tablets have demonstrable advantages transferable to the users such 
as the ease to administer and also provide relatively better stability. In the case of liquids, this 
provides an easy entry to new players because it entails simple manufacturing processes. Owing to 
the special regulatory requirements for production of beta-lactam products, i.e. separate and 
dedicated production units, only four companies in Kenya are producing these products. Though they 
have mastered production of these products overtime because they do not necessarily require 
sophisticated technology, the low coverage of the KEML products suggests narrow focus driven by 
market dynamics that are largely public oriented.  
 
There is little evidence that LPPs have invested in new technology to allow them to introduce new 
products and formulations in the EML which offers a great potential for growth considering needs 
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occasioned by new disease burdens. For example, cancer is now among the top-10 killer disease in 
Kenya according to Kenya National Bureau of Statistics15, but there are no programs to encourage 
investments in the development of anticancer products locally. Such investments could include PPPs, 
JVs and technology transfers. The focus on products for management of communicable diseases is not 
surprising considering that the market demand exists due to the high infectious disease burden. For 
example, in Kenya the leading cause of morbidity are diseases of the respiratory system which 
accounted for 39.3% of the total disease incidences in 2018.16 The focus on a narrow set of products 
suggests that there is no link between the disease management and pharma manufacturing sector in 
terms of key priorities to address national disease burden. This arises from the fact that priorities are 
not adequately articulated, and the government is not driving the industry towards producing 
medicines according the disease burden data. Notably the local industry continue to focus on a few 
therapeutic areas at the expense of the bigger needs as per the disease burden profile of the region 
and country. The average production capacity utilization of 43% for non -beta lactam products is an 
improvement from the last assessment of 2014Error! Bookmark not defined. where it was at 28% (for all dosage 
forms including semisolids, dry powders and beta lactam products). This is a 15% increase in line with 
the projection in 2014 (37%) by Vugigi et al.Error! Bookmark not defined. That notwithstanding, these 
manufacturers compete for the same market (largely public) and product range suggesting uptake of 
small portions on their products. This contributes to the underutilization of the available production 
capacity. Most manufacturers do not produce ARVs. This is because most ARVs and antimalarials are 
currently donor-funded and have a WHO PQ requirement. Unfortunately, LPPs who are GMP 
competent and compliant to supply these products are disadvantaged due to PQ requirements which 
is quite limiting as such, manufacturers may not be keen to invest in the technology to develop new 
products for such diseases. For example, antiretrovirals and antimalarials fixed dosage form (FDC) 
formulations require additional changes of parts on existing machines or new sophisticated 
technology for development that necessitates a clear view of the return on investment. Additionally, 
unpredictable treatment regimens (e.g. discontinuation of amodiaquine, lamivudine, zidovudine & 
lamivudine) further complicates the decision to invest in the development of such products. The LPPs 
are hesitant to engage in new molecule development that have high potential safety risks and/or 
narrow therapeutic indices and high product development costs.  For instance, new product 
development would require technology, skilled personnel, and Bioequivalence (BE) studies in order to 
build confidence in the quality, efficacy and safety of the products. Furthermore, prescriber’s 
requirement for interchangeability evidence is another risk that may lead to poor market penetration 
                                                             
15 Economic Survey 2018 Highlights, KNBS 2018. 
16 Economic Survey report, KNBS 2019. 
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of the new products.  All these contribute to suppressed attempt at investing more resources for 
product development by local industry. 
 
Another important factor is on lack of exploitation and working patents which bear commercial risk 
and cost of litigation unless compulsory licensing has been acquired as per the TRIPS flexibilities and 
Doha agreement. The Local industry takes a precautionary measure to wait till patent expiry unless 
the government declares a national disaster of a disease whose product is under patent regime. The 
Kenyan manufacturer (Cosmos) justified the application for voluntary/ compulsory licensing (TRIPS 
Flexibility) arising from public demand and declaration of HIV as a national disaster.  
 
The Insufficient and fragmented policies in support of innovation have contributed to meager 
investment in product development. In addition, there are lost opportunities when policy and 
implementations are not coherent. For example; in the 1990s, Kenya had several manufacturers 
producing anti-Malarial products. Due to massive resistance to chloroquine and later Sulphadoxine – 
Pyrimethamine in early 2010s, there was a deliberate change in therapy to the artemisinin-based 
combination therapy (ACT). However, the local production of antimalarial products decreased 
substantially as a result of this change17.  The main reason being that Artemether/ Lumefantrine (AL) 
procurement by the government is donor funded for which most local manufacturers are not eligible 
due to international prerequisites that participation is open only to manufacturers with WHO 
prequalification (PQ) status.  Malaria at that time was the leading cause of morbidity. There were no 
initiatives for local sources for AL or other recommended therapies for malaria.  Meri Koivusalo and 
Maureen Mackintosh cite malaria as one of the failure vertical programs18 for lack of integration with 
other strategies.  It is important to recognize that changes in policy at international fora may be 
detrimental to an unprepared local industry. There is need to review and improve exisitng  
pharmaceutical industry relevant policies and harmonize regional interventions to ensure steady 
growth of LPPs and access to quality and affordable medicines. This may require development of  a 
tangible framework for  investiment in the pharmaceutical sector and additional incentives in order 
catalyse growth and expansion of  the industry’s scope to address disease burden and improve 
product portiforlio.  
 
                                                             
17 Sarah Vugigi Thesis 
18Global public action in health and pharmaceutical policies: politics and policy priorities IKD Working Paper No. 
45 February 2009 Meri Koivusalo and Maureen Mackintosh 
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In spite of the adequate skills-mix for the current level of production of essential medicines, there 
remains a challenge for the industry in view of the need to move into robust product development 
work. As such, the training institutions (both public and private) need to re-look at their curriculum to 
address industry needs. Additionally, the current technological advancements leading to automation, 
production of targeted dosage forms and process efficiencies require skilled persons for operation 
and maintenance. Acquisition of these skills will lead to a new era of modernization in pharmaceutical 
production. Thus, there is need for institutions to establish curricula that is tailored towards providing 
training that meets the requirements for the industry. Furthermore, collaboration with the academic 
and training institutions is essential to ensure that the curriculum addresses these needs.  Some of the 
specialized  and practical skills may be imparted  through short courses 
 
To  incourage investment in GMP compliance and GMP enforcement, a  pragmatic industry accepted 
approach is necessary. The categorization plan developed by UNIDO in the Kenya GMP roadmap 
(categorization into A; B; C - Figure 3) could be adopted to ensure  compliance  with GMP while at the 
same time support companies to make incremental GMP improvents. This  will provided a way of 
determining the risk inherent in consistently manufacturing quality products such that a site with 
sufficient infrastructure and quality systems is rated as low risk and most likely to produce quality 
products and vice versa. In addition, this categorization of facilitates, the GMP inspector/regulator can 
make priorities for follow-up inspections, licensing of premises and choice of products.  
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Figure 3. Categorization model for gradual industry growth and production of -quality medicines. 
Source: Author  
 
Through the stepwise approach to GMP improvements, structured incentives can be introduced for 
different levels of categorization to drive compliance. In such a scheme, category A and B producers 
may be awarded to produce some critical EML products subject to capacity and GMP requirements, 
while those in category C are supported to produce low risk products subject to the same 
requirements as for A & B. As the companies invests in GMP, and capacity, they can apply to be 
considered for the higher category production. Establishment of a framework for attainment of 
stringent regulator status of the NMRA  in the various countries in the region will be essential for 
implementation  of the categorization process.  
 
The current disconnect between the national priorities and the local pharmaceutical industry arises 
from the fact that government is not driving the industry towards manufacturing products according 
the public sector needs.  This situation is aggravated by lack of linkage between the industry and 
academia/research institutions. The weaknesses stated herein   may be mitigated through 
stablishment of industry-research institution partnership for product innovation and research in line 
with the public health needs, especially essential medicines. The government should derive  the R&D 
agenda for the pharmaceutical industry. There is need to establish a  structured  process to  collect, 
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synthesize and disperse  data that is vital to guide industry and academic/research institutions  on  
national priority  R&D needs. This  necesitates a symbiotic linkage between universities/research 
institutions  and the pharma  industry on colloberative arrangements and sharing of knowledge in 
health and pharmaceutical research priorities  for development. There is need to ensure that each 
player/stakeholder is benefiting from the partnership and this way it will be sustainable.  However, it 
is the responsibility of  pharmaceutical industry to proactively develop a blue print  for development 
of  industry from all spheres including infrustructure, machinery & equipment, and GMP standards. 
 
Conclusion 
The local pharmaceutical industry in the EAC region has limited capacity  to produce sufficient   
esssential medicines  for domestic market. Establishment of a symbiotic linkage between 
universities, reseach institutions  and industry on colloberative arrangements in 
pharmaceutical research is necessary for improving  the product range. The government 
should derive the research agenda in line with national priorities. 
 
Study Limitation 
Pharmaceutical manufacturers and KIIs in Uganda, Tanzania and Ethiopia were informed of the same 
study. Unfortunately, not much was achieved owing non-responsiveness presumably due to 
confidentially concerns, internal policies and/or phobia. Notably, data sharing culture is sub-optimal in 
the region. As a counter measure, the team used the secondary data/literature and public reference 
materials for these countries. Similarly, some companies in Kenya did not share their product list or 
even HR information because of confidentiality concerns. 
-end- 
